Skip to main content

A Study of Erdafitinib Versus Investigator Choice of Intravesical Chemotherapy in Participants Who Received Bacillus Calmette-Guérin (BCG) and Recurred With High Risk Non-Muscle-Invasive Bladder Cancer (NMIBC)

Trial Status: Active

The purpose of this study is to evaluate recurrence-free survival (RFS) in participants treated with erdafitinib vs Investigator's Choice, for participants with high-risk non-muscle-invasive bladder cancer (NMIBC) who harbor fibroblast growth factor receptor (FGFR) mutations or fusions, and who recurred after bacillus calmette-guerin (BCG) therapy.

Inclusion Criteria

  • Histologically confirmed, recurrent, non-muscle-invasive urothelial carcinoma of the bladder. Variant pathology are allowed
  • Tumor with specified fibroblast growth factor receptor (FGFR) mutations or fusions
  • Bacillus Calmette- Guerin (BCG)-unresponsive after adequate BCG therapy or BCG experienced participants
  • Refuses or is not eligible for cystectomy (Cohort 1 and Cohort 2 only)
  • Eastern Cooperative Oncology Group (ECOG) performance status Grade 0-1
  • Must sign an informed consent form (ICF) (or their legally acceptable representative must sign) indicating that he or she understands the purpose of, and procedures required for, the study and is willing to participate in the study
  • A woman of childbearing potential must have a negative pregnancy test (beta-hCG [beta-human chorionic gonadotropin]) (urine or serum) within 7 days before randomization (Cohort 1) or the first dose of study drug (Cohort 2 and Cohort 3)
  • Adequate bone marrow, liver, and renal function as specified in the protocol

Exclusion Criteria

  • Histologically confirmed, muscle-invasive (T2 or higher stage) urothelial carcinoma of the bladder
  • Histopathology demonstrating any small cell component, pure adenocarcinoma, pure squamous cell carcinoma, or pure squamous CIS of the bladder
  • Prior treatment with an FGFR inhibitor
  • Active malignancies other than the disease being treated under study. The only allowed exceptions are: (a) skin cancer treated within the last 24 months that is considered completely cured (b) adequately treated lobular carcinoma in situ (LCIS) and ductal CIS (c) history of localized breast cancer and receiving antihormonal agents, or history of localized prostate cancer (N0M0) and receiving androgen deprivation therapy
  • Current central serous retinopathy or retinal pigment epithelial detachment of any grade


Los Angeles
Los Angeles County-USC Medical Center
Status: ACTIVE
Contact: Cheryl Kefauver
Phone: 323-865-0845
USC / Norris Comprehensive Cancer Center
Status: ACTIVE
Contact: Cheryl Kefauver
Phone: 323-865-0845


Emory University Hospital / Winship Cancer Institute
Status: ACTIVE


Kansas City
University of Kansas Cancer Center

New York

Montefiore Medical Center-Weiler Hospital
Status: ACTIVE


Ohio State University Comprehensive Cancer Center


Fred Hutch / University of Washington Cancer Consortium
Status: ACTIVE

This study enrolls participants with high risk NMIBC and FGFR mutations or fusions.

Erdafitinib is an oral pan-fibroblast growth factor receptor (FGFR) 1-4 inhibitor with

demonstrated clinical activity in participants with solid tumors, including urothelial

carcinoma, with alterations in the FGFR pathway. In Cohort 1, participants will be randomized

to erdafitinib or to Investigators Choice (intravesical gemcitabine or intravesical

MMC/hyperthermic MMC). The study consists of Screening period, Treatment Phase and Follow-up


Trial Phase Phase II

Trial Type Treatment

Lead Organization
Janssen Research & Development, LLC

  • Primary ID CR108699
  • Secondary IDs NCI-2020-00674, 42756493BLC2003, 2019-002449-39
  • ID NCT04172675